FDA approves Medtronic's Captivia to deliver new Talent
This article was originally published in Clinica
Executive Summary
Medtronic's Captivia delivery system is now available in the US, after the FDA granted a premarket approval (PMA) supplement for its use with the firm's Talent thoracic stent graft. The Talent Captivia system is used to repair thoracic aortic aneurysms, bulges in the artery that can rupture if left untreated. Captivia is already available in Canada and Europe, where it is used to deliver the Valiant thoracic stent graft; however, Valiant is not yet approved in the US. The Talent stent has been available in the US since 2008 (www.clinica.co.uk, 25 April 2008), but was previously sold in smaller sizes and administered using another delivery system. Talent is now available in lengths up to 215mm.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.